Scholars Central

CommentaryPublished 1 Sep 2022

Efficacy of Etoposide Against Doxorubicin Induced Cardiotoxicity in H9c2 Cardiomyoblasts

Authors: Sara Shabana

Anatomy & Physiology: Current Research

Volume 12 · Issue 9 · Pages 1–2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Doxorubicin (DOX), a broadly utilized anticancer medication, has been related with cardiotoxicity. As of late, DOX-prompted cardiotoxicity has been ascribed to topoisomerase II (TOPII)-β articulation and movement. In our examination, we researched the impact of restraining TOPII in weakening the DOX actuated cardiotoxicity. H9c2 cardiomyoblasts were treated with 1 or 2 μM DOX ETO. Cardiotoxicity was surveyed by inspecting cell reasonability utilizing the MTT measure, hypertrophy of gem violet recolored cardiomyoblasts and ROS creation. DOX instigated a portion subordinate expansion in cardiotoxicity as demonstrated by the huge decrease in cell suitability DOX versus 100% control.

Subjects

Education

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Anatomy & Physiology: Current Research.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalAnatomy & Physiology: Current Research
  • SubjectEducation
  • BylineArticles whose byline prints “Sara Shabana”